We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mast Group Launches MAST ISOPLEX CRE-Art Kit for Rapid Molecular Detection of Carbapenemase Producing Organisms

By LabMedica International staff writers
Posted on 23 Dec 2019
Mast Group Ltd. More...
(Liverpool, UK) announced the expansion of its molecular product portfolio with the launch of the new MAST ISOPLEX CRE-ART kit for the rapid molecular detection of carbapenemase producing organisms (CPOs).

Mast is a manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing. The company manufactures microbiology and molecular biology products, as well as other infectious disease and autoimmune diagnostics, using a variety of technologies.

The new MAST ISOPLEX CRE-ART is a loop mediated isothermal amplification (LAMP) kit for the detection and characterization of the seven most prevalent carbapenemase families: OXA-48, OXA-23, OXA-24/40, KPC, VIM, NDM and IMP. With ready-to-use with lyophilised pellets containing all primers and reagents, it provides rapid results with a 15-minute hands on time and a 30-minute run time. MAST ISOPLEX CRE-ART uses LAMP to provide an alternative to PCR technologies for the molecular detection of CPOs to make testing accessible to laboratories with limited resource and experience.

The company’s additional related MAST products include MAST CARBA PAcE – a rapid, simple and cost-effective solution for carbapenemase detection in Pseudomonas, Acinetobacter and Enterobacterales; MASTDISCS Combi ESBL Set (EUCAST) – with new recommended disc potencies as highlighted by EUCAST; MASTDISCS Combi AmpC, ESBL & Carbapenemase Detection Set - a combination six disc system that has been developed for the detection of Gram-negative resistance in Enterobacterales; MASTDISCS Combi Carba plus – for the detection of carbapenemase and OXA-48 enzyme production in Enterobacterales; and MAST ICT Indirect Carbapenemase Test – a screening test for the detection of carbapenemase production in Enterobacterales, Pseudomonas spp. and Acinetobacter spp.

Related Links:
Mast Group Ltd.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.